All Reports Events Blogs Videos
Showing 55 results
  • Thematic Report
    May 04, 2026

    The global Clinical Research Organization (CRO) market is undergoing a transformation, shaped by rising clinical trial complexity, increasing regulatory requirements, and growing demand for faster, more efficient drug development. CROs continue to play a pivotal role…
  • Viewpoint
    April 28, 2026

    The global safety database market is at an inflection point, driven by increasing complexities in Pharmacovigilance (PV) operations, growing regulatory expectations, and rapid expansion of data sources such as real-world evidence, digital health tools, and patient-generated…
  • Thematic Report
    March 30, 2026

    The Global Capability Center (GCC) model is rapidly evolving, with enterprises expanding GCC mandates beyond operational efficiency toward innovation and enterprise-wide strategic impact. As GCCs mature and move up the value chain, enterprises are increasingly leveraging…
  • Thematic Report
    Dec. 15, 2025

    The Global Capability Center (GCC) landscape is on a sustained growth path, with offshore-nearshore centers expected to rise from around 6,000 in 2024 to nearly 7,000 by 2027. Many enterprises are exploring GCCs to secure talent,…
  • PEAK Matrix®
    Nov. 05, 2025

    The Global Capability Center (GCC) setup market continues to gain momentum, with India maintaining its position as the leading destination for GCC setups, supported by its deep talent base, cost efficiency, regulatory maturity, and robust digital…
  • Market Insights™
    Nov. 05, 2025

  • Blog
    Nov. 02, 2025

    The clinical outsourcing market is undergoing a transition with the emergence of specialist-focused Clinical Research Organizations (CROs). A specialist CRO concentrates its expertise in a defined area, such as a therapeutic focus, trial phase or technology, or geographic niche, rather than offering broad,…
  • State of the Market
    Oct. 01, 2025

    The surge in case volumes, more stringent regulatory demands, and therapeutic areas’ rising complexities are significantly transforming pharmacovigilance (PV). As the industry adapts to more tailored reporting requirements and longer patient monitoring periods, enterprises are under…
  • PEAK Matrix®
    Sep. 30, 2025

    Global Capability Centers (GCCs) are rapidly evolving from cost-focused delivery hubs into strategic business transformation enablers. They now drive enterprise-wide innovation, enhance customer and employee experiences, and deliver measurable business impact. Key trends shaping this evolution…
  • Provider Compendium
    Sep. 30, 2025

    In recent years, life sciences enterprises have reoriented their R&D investments, prioritizing pipeline efficiency and a strategic focus on large and novel molecules. This shift has intensified efforts around cost containment and created a stronger need…
  • Provider Compendium
    Sep. 16, 2025

    Pharmacovigilance (PV) operations have become a strategic priority for life sciences enterprises facing heightened regulatory scrutiny, evolving safety standards, and growing complexity across global markets. This report provides an in-depth assessment of 12 leading PV service…
  • Webinar Deck
    July 31, 2025

    Life sciences commercial teams are facing tighter budgets, faster launch cycles, and growing pressure to prove ROI from every investment and engagement. In this high-stakes environment, a new breed of specialist providers is stepping up, reshaping…
  • Event
    July 29, 2025

    Life sciences commercial teams are facing tighter budgets, faster launch cycles, and growing pressure to prove ROI from every investment and engagement. In this high-stakes environment, a new breed of specialist providers is stepping up, reshaping…
  • LinkedIn Live
    July 24, 2025

    Watch on LinkedIn Global Capability Centers (GCCs) in India rapidly evolved from cost-efficient service hubs to strategic centers of innovation, product development, and digital transformation for global enterprises. As this evolution accelerated, talent development became a…
  • PEAK Matrix®
    July 16, 2025

    In recent years, life sciences enterprises have reprioritized and overhauled their R&D investments. They now focus on streamlining their pipelines and shifting toward new and large molecules. This transformation has compelled aggressive cost containment initiatives, prompting…
  • Viewpoint
    June 12, 2025

    Life sciences enterprises are increasingly turning to Real-world Evidence (RWE) as an essential input for decision-making across the product life cycle – from early-stage R&D to post-market access and safety. RWE offers validated insights into treatment…
  • Blog
    May 23, 2025

    On May 12, 2025, President Donald Trump signed a high-impact executive order titled “Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients.” The order directed the U.S. Department of Health and Human Services (HHS) to implement a…
  • PEAK Matrix®
    April 03, 2025

    Pharmacovigilance (PV) has evolved into a strategic imperative, driven by intensified regulatory scrutiny and an increasing focus on patient safety. Pharmaceutical companies now face a rapidly evolving landscape characterized by rising adverse event volumes, fragmented real-world…
  • LinkedIn Live
    Feb. 13, 2025

    Watch On LinkedIn Step into the future in this insightful LinkedIn Live with Everest Group experts Hrishi Raj Agarwalla, Vice President, and Ashish Sehdev, Vice President. Join this virtual session as they decode the market shifts…
  • Feb. 03, 2025

    The nasscom GCC Conclave 2025 nominations period is nearly here! Opening on Feb 4, 2025, the nominations will open for GCC leaders to put their businesses forward for recognition. Supported by Strategic Partner Everest Group, the…

Items per page